Extended Data Fig. 3: Liver fat and hepatic expression of pro-inflammatory cytokine (TNFA, IL1B, IL12A, IL12B, IFNG), anti-inflammatory cytokine (IL10), inflammatory cell infiltrate marker (CCL2, CCL11, CXCL1, CXCL9), inflammatory cell marker (CD4, CD68), and fibrogenic (ACTA2, COL1A1, COL3A1) genes in the CDAHFD rat fibrosis model relative to chow-fed rats. | Nature Medicine

Extended Data Fig. 3: Liver fat and hepatic expression of pro-inflammatory cytokine (TNFA, IL1B, IL12A, IL12B, IFNG), anti-inflammatory cytokine (IL10), inflammatory cell infiltrate marker (CCL2, CCL11, CXCL1, CXCL9), inflammatory cell marker (CD4, CD68), and fibrogenic (ACTA2, COL1A1, COL3A1) genes in the CDAHFD rat fibrosis model relative to chow-fed rats.

From: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Extended Data Fig. 3

a, Relative change in hepatic triglycerides (n = 12 per group). Relative expression of b, ACTA2 (n = 12 per group), c, COL1A1 (n = 12 per group), d, IL10 (control diet n = 10, vehicle n = 11, PF-05221304 n = 11, PF-06865571 n = 11, and PF-05221304 and PF-06865571 co-administration n = 10), e, CCL2 (n = 12 per group), f, CCL11 (n = 12 per group), g, TNF (control diet n = 11, vehicle n = 12, PF-05221304 n = 11, PF-06865571 n = 12, and PF-05221304 and PF-06865571 co-administration n = 11), h, CD4 (control diet n = 11, vehicle n = 12, PF-05221304 n = 11, PF-06865571 n = 12, and PF-05221304 and PF-06865571 co-administration n = 11), i, IL1B (n = 12 per group), j, CD68 (control diet n = 11, vehicle n = 12, PF-05221304 n = 10, PF-06865571 n = 12, and PF-05221304 and PF-06865571 co-administration, n = 12), k, IL12A (n = 12 per group), l, IL12B (control diet n = 11, vehicle n = 10, PF-05221304 n = 11, PF-06865571 n = 11, and PF-05221304 and PF-06865571 co-administration n = 12), m, IFNG (n = 12 per group, except control diet n = 11), n, CXCL1 (n = 12 per group), o, CXCL9 (control diet n = 12, vehicle n = 10, PF-05221304 n = 11, PF-06865571 n = 12, and PF-05221304 and PF-06865571 co-administration n = 12), p, COL3A1 (control diet n = 11, vehicle n = 12, PF-05221304 n = 10, PF-06865571 n = 11, and PF-05221304 and PF-06865571 co-administration n = 10). Data are mean (standard error). Statistical significance based on ANOVA model adjusting for unequal variances between groups. ACTA2, alpha smooth muscle actin; ANOVA, analysis of variance; choline-deficient, amino acid-defined, high-fat diet; IFN, interferon; IL, interleukin; PF’1304, PF-05221304 monotherapy; PF’5571, PF-06865571 monotherapy; PF’1304 + PF’5571, PF-05221304 and PF-06865571 co-administration; TNF, tumor necrosis factor.

Source data

Back to article page